|
Prosonix Features on WebTV |
 |
 |
 |
|
Written by Christian Jones
|
|
Friday, 19 December 2008 11:41 |
|
|
|
Last Updated on Saturday, 17 January 2009 15:52 |
|
|
Prosonix & Syrris in Marketing Partnership |
|
|
|
|
Written by Graham Ruecroft
|
|
Friday, 19 December 2008 11:45 |
 Prosonix Ltd (Oxford, UK) and Syrris (Royston, UK) are delighted to announce a new marketing partnership which positions Syrris as the prime channel to market for Prosonix’s new SonoLabTM laboratory scale sonocrystallization and sonoprocessing equipment.
|
|
Last Updated on Monday, 19 January 2009 19:38 |
|
New SonoLab Development Suite Launched |
|
|
|
|
Written by Graham Ruecroft
|
|
Friday, 19 December 2008 12:35 |
 Prosonix Launch New SonoLab TM Laboratory Scale Sonocrystallization Development Suite at CPHI Worldwide 2007 As part of the drive to make commercially viable sonocrystallization solutions easily accessible to the research and development activities, Prosonix [Oxford, UK] have launched a suite of manual, semi-automated, and fully automated sonocrystallization equipment. Sonocrystallizreadation technology allows chemists to control particle size, morphology and polymorphs.
|
|
Last Updated on Saturday, 17 January 2009 23:39 |
|
|
Prosonix Appoints Dr Jim Phillips as Non-Executive Chairman |
|
|
|
|
Written by Graham Ruecroft
|
|
Friday, 19 December 2008 11:48 |
 Prosonix, (Oxford, UK) leader in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries, are delighted to announce the appointment of Dr Jim Phillips to the key post of Non-Executive Chairman.
Prosonix Ltd (Oxford, UK) is delighted to announce a new agreement for the application of its proprietary ultrasonic particle engineering technology in the pharmaceutical industry. This new agreement has been concluded with Aeropharm (Rudolstadt, Germany) and is concerned with the development and manufacture of a new generation of “difficult-to-make” generic products. According to a recent industry report, the market size for inhaled medicines is expected to rise to $58 billion in 2012. With a significant portion of these revenues available for near term generic substitution, and inhaled drug delivery representing one of the most difficult material science challenges from an equivalence perspective, there is an ideal opportunity to leverage a new ultrasonic particle engineering led approach to generate lasting and significant commercial advantage.
|
|
Last Updated on Monday, 19 January 2009 19:37 |
|
Prosonix Ltd Completes £5M Funding Round |
|
|
|
|
Written by Graham Ruecroft
|
|
Friday, 30 November 2007 00:00 |
 Prosonix Ltd (Oxford, UK), acknowledged leader in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries, have today successfully completed a £5 million total funding round designed to underpin and drive the accelerated future growth plans of the business.
|
|
Last Updated on Monday, 19 January 2009 19:39 |
|
|
|
|
<< Start < Prev 1 2 3 4 5 6 7 8 9 Next > End >>
|
|
Page 4 of 9 |
David Hipkiss Prosonix CEO discusses the benefits of the Prosonix Sonocrystallization technology for the preparation of microcrystalline and mescopic particles of Active Pharma Ingredients with Nick Taylor of Inpharmatechnologist.com
